LIVERATION

LIVERATION is a comprehensive, practical, and multinational clinical trial spanning six countries, with the objective of investigating if the enlargement of the ablated margin through radiofrequency can reduce the recurrence of Colorectal Cancer Liver Metastasis (CRLM) and enhance patient longevity.

Colorectal cancer (CRC) is the third most common tumour in men and the second in women, with an estimate of 1.9 million new cases worldwide (450K in Europe) and approximately 900,000 deaths in 2020. Hepatic metastases develop in approximately 50% of colorectal cancer cases.

The liver, in addition to being the most common site of metastases, is also the first and only area of spread in 30–40% of patients.Surgery is considered the gold standard treatment and the only potentially curative option for colorectal liver metastases (CRLM).

LIVERATION leverages a prospective pragmatic clinical trial coordinated by expert clinicians and surgeons on liver cancer that had achieved promising preliminary results: a reduction of cancer local recurrence by adding an additional coagulation of the margin (ACM) with radiofrequency (RF) ablation devices compared to conventional hemostatic techniques in a retrospective clinical trial.

The main aim of LIVERATION is to evaluate the real-world effectiveness of ACM after liver resection in order to decrease liver cancer recurrence through a pragmatic clinical trial.

Population: adult | Intervention type: therapeutic procedural